Sartorius Stedim Biotech S.A. reported increased net profit for the first half of 2025, with earnings per share rising to 2.24 euros compared to 1.34 euros last year. Underlying net profit and earnings per share also saw significant growth, with sales revenue increasing to 2.20 billion euros from 2.03 billion euros in the previous year. The company raised its full-year outlook, now expecting sales revenue growth of about 9% and an underlying EBITDA margin of roughly 31%. Sartorius Stedim Biotech closed trading 1.70% higher at $185.95 on the Paris Stock Exchange.

Read more at Nasdaq.: Sartorius Stedim Biotech Earnings Up In H1; Lifts FY25 Outlook